Please amend the claims as follows:

Please cancel claims 8, 11, 16, 26, 28, 29 and 37-51.

Please add new claims 52-70.

1-51. **(Canceled)**

52. **(New)** A composition comprising active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins and inactive LT-β-R-Ig fusion proteins, wherein no more than 30% of the LT-β-R-Ig fusion proteins are inactive.

53. **(New)** The composition of claim 52, wherein no more than 17% of the LT-β-R-Ig fusion proteins are inactive.

54. **(New)** The composition of claim 52, wherein no more than 10% of the LT-β-R-Ig fusion proteins are inactive.

55. **(New)** The composition of claim 52, wherein no more than 6% of the LT-β-R-Ig fusion proteins are inactive.

56. **(New)** The composition of any one of claims 52-54, wherein the active LT-β-R-Ig fusion proteins are recognized by a functional specific antibody.

57. **(New)** The composition of any one of claims 52-54, wherein the LT-β-R-Ig fusion protein comprises an Fc domain.

58. **(New)** A pharmaceutical composition comprising the composition of claim 57, and a pharmaceutically acceptable carrier.

59. **(New)** The composition of any one of claims 52-54, wherein the Fc domain is of an IgG1 isotype.

62. **(New)** A pharmaceutical composition comprising the composition of claim 59, and a pharmaceutically acceptable carrier.

63. **(New)** A composition comprising active and inactive lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins, wherein no more than 30% LT-β-R-Ig fusion proteins are inactive, and wherein the active LT-β-R-Ig fusion proteins are obtained by culturing a mammalian host cell transformed with DNA encoding the LT-β-R-Ig fusion protein in a culture system having a temperature of about 27° C to about 35° C

64. **(New)** The composition of claim 63, wherein no more than 17% of the LT-β-R-Ig fusion proteins are inactive.

65. **(New)** The composition of claim 63, wherein no more than 10% of the LT-β-R-Ig fusion proteins are inactive.

66. **(New)** The composition of claim 62, wherein no more than 6% of the LT-β-R-Ig fusion proteins are active.

67. **(New)** The composition of any one of claims 63-66, wherein the LT-β-R-Ig fusion protein comprises an Fc domain.

68. **(New)** A pharmaceutical composition comprising the composition of claim 67, and a pharmaceutically acceptable carrier.

69. **(New)** The composition of any one of claims 63-66, wherein the Fc domain is of an IgG1 isotype.

70. **(New)** A pharmaceutical composition comprising the composition of claim 69, and a pharmaceutically acceptable carrier.